The future of hemophilia A treatment: From Jivi® to gene therapy

EAHAD 2020 Congress | The Hague, Netherlands
Wednesday, February 5 | 13:45–15:00 | Mississippi Room, World Forum

Join us for a review of the latest Jivi® (damoctocog alfa pegol) data from the PROTECT VIII study; learn about breaking head-to-head data; and explore the first clinical data from Bayer’s gene therapy, BAY 2599023.

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>SPEAKER</th>
</tr>
</thead>
</table>
| Foundation for the future: Setting the standard in hemophilia A with rFVIII | Robert Klamroth (chair)  
Vivantes Klinikum im Friedrichshain, Germany |
| PEGylation and PK: The science behind Jivi®                           | Diego Fornasari  
University of Milan, Italy |
| 6 years of experience with Jivi®: PROTECT VIII                       | Mark Reding  
University of Minnesota, USA |
| Jivi® in clinical practice: Real-world evidence and the patient perspective | Jonathan Ducore  
UC Davis Children’s Hospital, USA |
|                                                                      | Natascha Marquardt  
Universitätsklinikum Bonn, Germany |
| Gene therapy: The ultimate innovation for patients                   | Steve Pipe  
University of Michigan, USA |
| Wrap-up and close                                                    | Robert Klamroth  
Vivantes Klinikum im Friedrichshain, Germany |

This meeting has been organized and funded by Bayer, Jivi®, BAYER, and the Bayer Cross are registered trademarks of Bayer.
December 2019 | MA-M_DAM-ALL-0131-1 | MA-M_DAM-NL-0010-1